Published in N Engl J Med on January 09, 1986
Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort. Br Med J (Clin Res Ed) (1988) 4.03
Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging. J Clin Invest (1989) 3.92
Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. J Clin Invest (1993) 3.19
Human immunodeficiency virus type 1 has an additional coding sequence in the central region of the genome. Proc Natl Acad Sci U S A (1988) 2.20
Increasing rates of obesity among HIV-infected persons during the HIV epidemic. PLoS One (2010) 1.75
Variations in Western blot banding patterns of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus. J Clin Microbiol (1987) 1.33
Interference with human immunodeficiency virus (HIV) replication by CD8+ T cells in peripheral blood leukocytes of asymptomatic HIV carriers in vitro. J Virol (1990) 1.30
An epitope in human immunodeficiency virus 1 reverse transcriptase recognized by both mouse and human cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1990) 1.28
Nonrandom development of immunologic abnormalities after infection with human immunodeficiency virus: implications for immunologic classification of the disease. Proc Natl Acad Sci U S A (1987) 1.24
Risk behavior-based model of the cubic growth of acquired immunodeficiency syndrome in the United States. Proc Natl Acad Sci U S A (1989) 1.20
Densitometric analysis of Western blot (immunoblot) assays for human immunodeficiency virus antibodies and correlation with clinical status. J Clin Microbiol (1987) 1.07
Elevated serum levels of soluble tumour necrosis factor receptors (sTNF-R) in patients with HIV infection. Clin Exp Immunol (1992) 1.05
Lack of enhancing effect of human anti-human immunodeficiency virus type 1 (HIV-1) antibody on HIV-1 infection of human blood monocytes and peritoneal macrophages. J Virol (1991) 1.00
Synthetic peptides define the fine specificity of the human immunodeficiency virus (HIV) gp160 humoral immune response in HIV type 1-infected chimpanzees. J Virol (1990) 0.96
Cutaneous malignancies among HIV-infected persons. Arch Intern Med (2009) 0.96
Nocturnal sleep EEG in patients with HIV infection. Eur Arch Psychiatry Clin Neurosci (1991) 0.92
Monitoring human immunodeficiency virus type 1-infected patients by ratio of antibodies to gp41 and p24. J Clin Microbiol (1989) 0.92
Impairment of colour contrast sensitivity and neuroretinal dysfunction in patients with symptomatic HIV infection or AIDS. Br J Ophthalmol (1993) 0.90
Cholangitis in the acquired immunodeficiency syndrome: report of two cases and review of the literature. Gut (1987) 0.87
Serologic evaluation of human immunodeficiency virus type 1-infected individuals from Argentina and the United States indicates a similar distribution of subgroup B isolates. J Clin Microbiol (1995) 0.87
Management of cerebral infection. J Neurol Neurosurg Psychiatry (1993) 0.86
Postmortem localization of HIV-1 RNA by in situ hybridization in lymphoid tissues of intravenous drug addicts who died unexpectedly. Am J Pathol (1993) 0.86
Lymphocyte subsets as surrogate markers in antiretroviral therapy. Infection (1991) 0.85
Individuals infected with HIV possess antibodies against IL-2. Immunology (1988) 0.85
Increased serum neopterin in patients with HIV-1 infection is correlated with reduced in vitro interleukin-2 production. Clin Exp Immunol (1990) 0.82
Isolation of Mycoplasma species from bronchoalveolar lavages of patients positive and negative for human immunodeficiency virus. J Clin Microbiol (1994) 0.82
Cell-mediated immunity to HIV-1 in Walter Reed stages 1-6 individuals: correlation with virus burden. Immunology (1993) 0.81
Tumour necrosis factor-alpha mediates blood-brain barrier damage in HIV-1 infection of the central nervous system. Mediators Inflamm (1992) 0.80
Soluble tumour necrosis factor receptors (sTNF-R) and HIV infection: correlation to CD8+ lymphocytes. Clin Exp Immunol (1993) 0.79
Impaired induction of the apoptosis-protective protein Bcl-xL in activated PBMC from asymptomatic HIV-infected individuals. J Clin Immunol (1997) 0.78
Continuous Antigenic Stimulation of DO11.10 TCR Transgenic Mice in the Presence or Absence of IL-1β: Possible Implications for Mechanisms of T Cell Depletion in HIV Disease. J Immunol (2015) 0.78
Human immunodeficiency virus (HIV)-related chronic relapsing inflammatory demyelinating polyneuropathy with multifocal unusual onion bulbs in sural nerve biopsy. A clinicomorphological study with qualitative and quantitative light and electron microscopy. Acta Neuropathol (1988) 0.78
In vitro activation of peripheral mononuclear cells by zinc in HIV-infected patients and healthy controls. Clin Exp Immunol (1992) 0.77
Phenotypical and functional evaluation of CD8+/S6F1+ T lymphocytes in haemophiliac individuals with HIV-1 infection. Clin Exp Immunol (1993) 0.77
Screening for CMV retinitis using chromatic discrimination thresholds and achromatic contrast sensitivity. Br J Ophthalmol (2000) 0.77
Validity of a self-reported history of a positive tuberculin skin test. A prospective study of drug users. J Gen Intern Med (2004) 0.76
Sequential Dysfunction and Progressive Depletion of Candida albicans-Specific CD4 T Cell Response in HIV-1 Infection. PLoS Pathog (2016) 0.76
Immunocytochemical demonstration of human immunodeficiency virus infected cells in the cerebrospinal fluid. J Neurol Neurosurg Psychiatry (1988) 0.75
Cardiac dysfunction in patients seropositive for the human immunodeficiency virus. West J Med (1991) 0.75
Epidemic human immunodeficiency virus (HIV) infection among intravenous drug users (IVDU). Yale J Biol Med (1988) 0.75
A Brief Chronicle of CD4 as a Biomarker for HIV/AIDS: A Tribute to the Memory of John L. Fahey. For Immunopathol Dis Therap (2016) 0.75
Progression of HIV-infection: markers or determinants. Trans Am Clin Climatol Assoc (1993) 0.75
Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS. Science (1986) 7.81
Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis (1972) 4.54
Human immunodeficiency virus infections among civilian applicants for United States military service, October 1985 to March 1986. Demographic factors associated with seropositivity. N Engl J Med (1987) 2.81
HTLV-III in symptom-free seronegative persons. Lancet (1984) 2.71
Effect of spectinomycin use on the prevalence of spectinomycin-resistant and of penicillinase-producing Neisseria gonorrhoeae. N Engl J Med (1987) 2.70
Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med (1987) 2.59
Serologic studies of meningococcal infection and polysaccharide vaccination. J Infect Dis (1971) 2.54
Seronegative secondary syphilis in a patient infected with the human immunodeficiency virus (HIV) with Kaposi sarcoma. A diagnostic dilemma. Ann Intern Med (1987) 2.35
Persistence of Treponema pallidum following penicillin G therapy. Report of two cases. JAMA (1976) 2.31
Type-restricted neutralization of molecular clones of human immunodeficiency virus. Science (1988) 2.31
Cross-reactivity of Neisseria gonorrhoeae and Neisseria meningitidis and the nature of antigens involved in the bactericidal reaction. J Infect Dis (1974) 2.24
Measurement of the false positive rate in a screening program for human immunodeficiency virus infections. N Engl J Med (1988) 2.22
Frequency of illness associated with epidemic hepatitis A virus infections in adults. Am J Epidemiol (1985) 2.20
Acoustic neuromas: results of current surgical management. Neurosurgery (1997) 2.12
False-positive Western blot tests for antibodies to HTLV-III. JAMA (1986) 2.07
Defective regulation of Epstein-Barr virus infection in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related disorders. N Engl J Med (1986) 2.03
Immunoenzymatic analysis by monoclonal antibodies of bacterial lipopolysaccharides after transfer to nitrocellulose. J Immunol Methods (1985) 1.93
Extreme lateral transcondylar approach: technical improvements and lessons learned. J Neurosurg (1994) 1.91
Variability of the lytic susceptibility of Neisseria gonorrhoeae to human sera. J Immunol (1977) 1.81
Chordomas and chondrosarcomas of the cranial base: results and follow-up of 60 patients. Neurosurgery (1995) 1.80
Frequent transmission of HTLV-III among spouses of patients with AIDS-related complex and AIDS. JAMA (1985) 1.76
Role of lipopolysaccharide and capsule in the serum resistance of bacteremic strains of Escherichia coli. J Infect Dis (1986) 1.73
Human immunodeficiency virus infections in teenagers. Seroprevalence among applicants for US military service. The Walter Reed Retrovirus Research Group. JAMA (1990) 1.67
Heterosexually acquired HTLV-III/LAV disease (AIDS-related complex and AIDS). Epidemiologic evidence for female-to-male transmission. JAMA (1985) 1.65
Gonococcal pilus vaccine. Studies of antigenicity and inhibition of attachment. J Clin Invest (1981) 1.62
Identification and characterization of a monoclonal antibody that neutralizes ricin toxicity in vitro and in vivo. Hybridoma (1994) 1.62
Inhibition of adherence of Neisseria gonorrhoeae by human genital secretions. J Clin Invest (1977) 1.61
Primary isolation and serial passage of hepatitis A virus strains in primate cell cultures. J Clin Microbiol (1984) 1.61
Chronic vaginal candidiasis in women with human immunodeficiency virus infection. JAMA (1987) 1.59
Increased antibiotic resistance of Neisseria gonorrhoeae in Korea. Antimicrob Agents Chemother (1976) 1.58
A novel surfactant nanoemulsion with broad-spectrum sporicidal activity against Bacillus species. J Infect Dis (1999) 1.51
Efficacy trial of a parenteral gonococcal pilus vaccine in men. Vaccine (1991) 1.50
Prevalence and incidence of HTLV-III infection in a prison. JAMA (1986) 1.48
Induction of human immunodeficiency virus type 1 expression in chronically infected cells is associated primarily with a shift in RNA splicing patterns. J Virol (1991) 1.48
Posterior fossa meningiomas: surgical experience in 161 cases. Surg Neurol (2001) 1.45
Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR Am J Roentgenol (1988) 1.41
Naturally occurring genotypes of the human immunodeficiency virus type 1 long terminal repeat display a wide range of basal and Tat-induced transcriptional activities. J Virol (1994) 1.40
Surgical treatment of basilar aneurysms. Neurosurgery (1979) 1.38
Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1. Proc Natl Acad Sci U S A (2003) 1.38
Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. J Immunol (1995) 1.37
Syphilis in the AIDS era. N Engl J Med (1987) 1.37
Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivo. Lancet (1985) 1.35
Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1. J Immunol (1994) 1.35
Congestive cardiomyopathy in association with the acquired immunodeficiency syndrome. N Engl J Med (1986) 1.34
Specificity of inhibition of epithelial cell adhesion of Neisseria gonorrhoeae. Infect Immun (1976) 1.33
Variations in Western blot banding patterns of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus. J Clin Microbiol (1987) 1.33
Induction of interleukin-6 during human immunodeficiency virus infection. Blood (1990) 1.32
Diagnosis of human immunodeficiency virus infection by immunoassay using a molecularly cloned and expressed virus envelope polypeptide. Comparison to Western blot on 2707 consecutive serum samples. Ann Intern Med (1987) 1.32
Human immunodeficiency virus type 1 cellular RNA load and splicing patterns predict disease progression in a longitudinally studied cohort. J Virol (1995) 1.30
Negative-strand RNA transcripts are produced in human immunodeficiency virus type 1-infected cells and patients by a novel promoter downregulated by Tat. J Virol (1994) 1.29
A prospective randomized trial of ofloxacin vs. doxycycline in the treatment of uncomplicated male urethritis. Sex Transm Dis (1989) 1.28
Endodermal cysts of the posterior fossa. Report of three cases and review of the literature. J Neurosurg (1998) 1.25
Differences in the interaction of HIV-1 and HIV-2 with CD4. J Acquir Immune Defic Syndr (1990) 1.24
Inhibition of clinically significant bacterial organisms in vitro by 2-acetylpyridine thiosemicarbazones. Antimicrob Agents Chemother (1980) 1.23
Meningococcal infections. 3. Studies of group A polysaccharide vaccines. Bull World Health Organ (1971) 1.23
Latex agglutination test for measurement of antibodies to meningococcal polysaccharides. Infect Immun (1972) 1.21
Antigenic specificity of antibodies in vaginal secretions during infection with Neisseria gonorrhoeae. J Infect Dis (1980) 1.20
Simple method for detection of penicillinase-producing Neisseria gonorrhoeae. J Clin Microbiol (1978) 1.20
The presence of unique DNA sequences after viral induction of leukemia in mice. (RNA tumor virus-nucleic acid hybridization-insertion of viral DNA). Proc Natl Acad Sci U S A (1974) 1.19
Relative inefficiency of soluble recombinant CD4 for inhibition of infection by monocyte-tropic HIV in monocytes and T cells. J Immunol (1990) 1.18
Translabyrinthine approach to skull base tumors with hearing preservation. Am J Otol (1993) 1.17
Surgical anatomy of the infratemporal fossa: the styloid diaphragm revisited. Neurosurgery (1998) 1.16
Genital antibody response to a parenteral gonococcal pilus vaccine. Infect Immun (1982) 1.14
The threat of infectious disease in Americans returning from Operation Desert Storm. N Engl J Med (1991) 1.14
Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine. A cost reduction strategy. JAMA (1985) 1.13
Clinical correlation of strain differentiation of Neisseria gonorrhoeae. J Infect Dis (1976) 1.13
Lack of attenuation of a candidate dengue 1 vaccine (45AZ5) in human volunteers. Am J Trop Med Hyg (1987) 1.13
Situational analysis of varying models of adherence support and loss to follow up rates; findings from 27 treatment facilities in eight resource limited countries. Trop Med Int Health (2010) 1.12
Isolation of HIV-1 from the blood of seropositive adults: patient stage of illness and sample inoculum size are major determinants of a positive culture. The Walter Reed Retroviral Research Group. J Acquir Immune Defic Syndr (1990) 1.11
The effect of chronic food and water restriction on open-field behaviour and serum corticosterone levels in rats. Lab Anim (2000) 1.11
Characterization of mouse monoclonal antibodies directed against Pseudomonas aeruginosa lipopolysaccharides. Antibiot Chemother (1971) (1985) 1.11
Long-term follow-up of patients with meningiomas involving the cavernous sinus: recurrence, progression, and quality of life. Neurosurgery (1996) 1.10
Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep (1980) 1.09
Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. J Clin Pharmacol (1986) 1.09
Decentralization of CD4 testing in resource-limited settings: 7 years of experience in six African countries. Cytometry A (2011) 1.08
Frequent isolation of HIV-1 from the blood of patients receiving zidovudine (AZT) therapy. N Engl J Med (1989) 1.08
Variations of the extreme-lateral craniocervical approach: anatomical study and clinical analysis of 69 patients. J Neurosurg (1999) 1.07
HIV-1 proviral genotypes from the peripheral blood mononuclear cells of an infected patient are differentially represented in expressed sequences. J Acquir Immune Defic Syndr (1993) 1.07
Real-time biospecific interaction analysis of antibody reactivity to peptides from the envelope glycoprotein, gp160, of HIV-1. J Immunol Methods (1992) 1.07
Quantification and pharmacokinetics of blood-brain barrier disruption in humans. J Neurosurg (1996) 1.06
Management and long-term outcome of adenoid cystic carcinoma with intracranial extension: a neurosurgical perspective. Neurosurgery (1996) 1.06
Immunogenic and antigenic properties of a heptavalent high-molecular-weight O-polysaccharide vaccine derived from Pseudomonas aeruginosa. Infect Immun (1994) 1.06
Vasospasm after cranial base tumor resection: pathogenesis, diagnosis, and therapy. Surg Neurol (1999) 1.05
Cranial base approaches to intracranial aneurysms in the subarachnoid space. Neurosurgery (1994) 1.04
Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection. J Infect Dis (1998) 1.04
Proteosomes, emulsomes, and cholera toxin B improve nasal immunogenicity of human immunodeficiency virus gp160 in mice: induction of serum, intestinal, vaginal, and lung IgA and IgG. J Infect Dis (1997) 1.03
Partial labyrinthectomy petrous apicectomy approach to neoplastic and vascular lesions of the petroclival area. Neurosurgery (1999) 1.02
The results of surgery for benign tumors of the cavernous sinus. Neurosurgery (1995) 0.99
Cranial chordomas: clinical presentation and results of operative and radiation therapy in twenty-six patients. Neurosurgery (1985) 0.99
Trends of HIV seroconversion among young adults in the US Army, 1985 to 1989. US Army Retrovirus Research Group. JAMA (1991) 0.99
Differences in attachment antigens of gonococci in reinfection. J Lab Clin Med (1979) 0.98
Comparison of antibody reactivity to human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in sera from HIV-1-infected individuals from Tanzania and from the United States. J Clin Microbiol (1992) 0.98